Cognition Therapeutics Inc (NASDAQ:CGTX) has a beta value of 1.24 and has seen 0.45 million shares traded in the recent trading session. The CGTX stock price is -555.56% off its 52-week high price of $2.95 and 24.44% above the 52-week low of $0.34. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.2 million shares traded. The 3-month trading volume is 1.54 million shares.
The consensus among analysts is that Cognition Therapeutics Inc (CGTX) is Buy stock at the moment, with a recommendation rating of 1.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.19.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cognition Therapeutics Inc (NASDAQ:CGTX) trade information
Sporting -0.29% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CGTX stock price touched $0.45 or saw a rise of 13.69%. Year-to-date, Cognition Therapeutics Inc shares have moved -75.69%, while the 5-day performance has seen it change 3.74%. Over the past 30 days, the shares of Cognition Therapeutics Inc (NASDAQ:CGTX) have changed -2.49%. Short interest in the company has seen 0.82 million shares shorted with days to cover at 1.07.
Cognition Therapeutics Inc (CGTX) estimates and forecasts
Figures show that Cognition Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -77.63% over the past 6 months, with this year growth rate of 0.00%, compared to 17.20% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -21.09% over the past 5 years.
CGTX Dividends
Cognition Therapeutics Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Cognition Therapeutics Inc (NASDAQ:CGTX)’s Major holders
Insiders own 0.54% of the company shares, while shares held by institutions stand at 24.53% with a share float percentage of 24.67%. Investors are also buoyed by the number of investors in a company, with Cognition Therapeutics Inc having a total of 41.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 1.15 million shares worth more than $1.9 million. As of 2024-06-30, VANGUARD GROUP INC held 3.4016% of shares outstanding.
The other major institutional holder is AWM INVESTMENT COMPANY, INC., with the holding of over 0.65 million shares as of 2024-06-30. The firm’s total holdings are worth over $1.08 million and represent 1.9268% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Sep 30, 2024, the former fund manager holds about 2.43% shares in the company for having 1.01 shares of worth $0.45 million while later fund manager owns 200.58 shares of worth $89377.0 as of Sep 30, 2024, which makes it owner of about 0.48% of company’s outstanding stock.
